Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 12 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $179.5, which forecasts a 5.48% increase in the stock price over the next year. The lowest target is $105 and the highest is $220.

Price Target: $179.5 (+5.48%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$105	$179.5	$190	$220
Change	-38.30%	+5.48%	+11.65%	+29.27%

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	6	6	6	7	7	7
Buy	3	3	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	2	2	1	1	1	1
Total	12	12	11	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gaurav Jain Barclays	Barclays	Buy Maintains $225 → $220	Buy	Maintains	$225 → $220	+29.27%	Jul 30, 2025
Gerald Pascarelli Needham	Needham	Strong Buy Reiterates $195	Strong Buy	Reiterates	$195	+14.58%	Jul 23, 2025
Faham Baig UBS	UBS	Hold Maintains $170 → $181	Hold	Maintains	$170 → $181	+6.36%	Jul 14, 2025
Simon Hales Citigroup	Citigroup	Strong Buy Maintains $188 → $200	Strong Buy	Maintains	$188 → $200	+17.52%	Jul 10, 2025
Jared Dinges JP Morgan	JP Morgan	Buy Maintains $175 → $190	Buy	Maintains	$175 → $190	+11.65%	Jul 10, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

42.28B

from 37.88B

11.61%

from 37.88B

Revenue Next Year

45.84B

from 42.28B

8.43%

from 42.28B

EPS This Year

7.70

from 4.52

70.34%

from 4.52

EPS Next Year

8.58

from 7.70

11.40%

from 7.70

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	28.69B	31.41B	31.76B	35.17B	37.88B	42.28B	45.84B	48.75B
Revenue Growth	-3.73%	9.45%	1.14%	10.74%	7.69%	11.61%	8.43%	6.35%
EPS	5.16	5.83	5.81	5.02	4.52	7.70	8.58	9.44
EPS Growth	11.94%	12.98%	-0.34%	-13.60%	-9.96%	70.34%	11.40%	10.10%
Forward PE	-	-	-	-	-	22.10	19.84	18.02
No. Analysts	-	-	-	-	-	23	22	16

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	43.7B	48.2B	52.2B
Avg	42.3B	45.8B	48.8B
Low	39.6B	42.3B	44.6B

Revenue Growth

Revenue Growth	2025	2026	2027
High	15.4%	14.1%	13.9%
Avg	11.6%	8.4%	6.4%
Low	4.6%	0.1%	-2.7%

EPS Forecast

EPS	2025	2026	2027
High	8.02	9.07	10.12
Avg	7.70	8.58	9.44
Low	7.15	7.94	8.65

EPS Growth

EPS Growth	2025	2026	2027
High	77.5%	17.8%	18.0%
Avg	70.3%	11.4%	10.1%
Low	58.3%	3.1%	0.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.